Glaukos Reports Revenue Growth in 2025 Second Quarter, Lifts Full-Year Guidance

Published on July 31, 2025
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the second quarter ending June 30, 2025. Net sales of $124.1 million in the second quarter of 2025 increased 30 percent on a reported basis, or 29 percent on a constant currency basis, compared with $95.7 million in the same period in 2024, the company advised. Glaukos also raised its full-year guidance and said it now expects full-year 2025 net sales to be in the range of $480 million to $486 million based on the latest foreign currency exchange rates, compared with its prior guidance of $475 million to $485 million.
Continue reading on website
Other news

Exonate plans to initiate phase 2b CLEAR-DE trial for EXN407 topical formulation for NPDR

July 30, 2025
The first-in-class, twice-daily topical formulation is intended for the treatment of non-proliferative diabetic retinopathy and diabetic macular edema.

A case of orthokeratology for high myopia

July 31, 2025
Paul Levine, OD, FAAO, FIAOMC, details a pediatric case of high myopia in which the patient's prescription had increased from –5.75 DS OU to OD –7.00 DS, OS –6.75 DS within a year.